“I am a doctor first,” emphasizes Hugo Sigman (75), who is also the owner of the Insud pharmaceutical group and a film producer. You are, you
"Boris Johnson launches new 'antivirals taskforce' to find and buy pills for infected patients to take at home" Capitulation on early medical therapy. British have lagged America for months and finally settle in on the inevitable 💉failure. Early C19Rx https://www.dailymail.co.uk/news/article-9491869/Coronavirus-Britain-pills-treat-Covid-autumn.html
Excellent paper on #fluvoxamine and COVID-19 published today. Primary author is Dean of School of Medicine at Emory University.
We already know it works. This paper covers the why it works so well. https://www.frontiersin.org/articles/10.3389/fphar.2021.652688/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE
Someday people will believe all the evidence.
Greetings and welcome. COVEXIT.com offers you independent global news and policy analysis regarding COVID-19, with emphasis on early treatments. Also, please subscribe below to our newsletter, so you receive updates about our coverage. Thanks!
We now have our first Covexit.com Podcast episode on Spotify!
We have a fast growing group on Telegram — https://t.me/covexitgroup
Join us also on ClubHouse! — (iPhone only)
https://www.joinclubhouse.com/club/covid-outpatient-care
RECOMMENDED/RECOMMANDÉS:
Webinar with Dr Brian Tyson and Dr George Fareed – Part 1
A Protocol for the Prevention and Early Treatment of COVID-19 in Nursing Homes
Un protocole pour la prévention et le traitement précoce du C19 dans les résidences pour aînés
Webinar with Professor Paul Marik: the Prevention & Outpatient Treatment of C19
Prophylaxie et Traitement Précoce du C19 – un Webinaire avec le Professeur de Médecine Paul Marik
Bonjour et bienvenue à COVEXIT.com, un site Web proposant des nouvelles mondiales indépendantes et une analyse des stratégies gouvernementales concernant le COVID-19, avec un accent particulier sur les traitements thérapeutiques précoces. Aussi, abonnez vous à notre newsletter, afin de recevoir des mises à jour! Merci!
